查看购物车
  • Traditional Chinese
  • English
  • Japanese
封面
市场调查报告书
商品编码
1612962

慢性肾臟病市场：按类型、适应症和最终用户划分 - 全球预测 2025-2030

Chronic Kidney Disease Market by Type (Diagnosis, Treatment), Indication (Chronic Interstitial Nephritis, Diabetic Nephropathy, Glomerulonephritis), End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 181 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

2023年慢性肾臟病市场价值为1,284.5亿美元，预计到2024年将达到1,365.6亿美元，复合年增长率为6.50%，到2030年将达到1996.4亿美元。

慢性肾臟病(CKD) 是一种以肾功能逐渐丧失为特征的长期疾病，由于糖尿病和高血压等因素，影响着全世界数百万人。 CKD 市场包括药品、诊断、透析机和肾臟移植，代表了医疗保健领域的巨大需求。 CKD 管理包括早期诊断、监测、治疗依从性以及专业诊所的咨询，满足医疗保健专业人员的需求并改善患者的治疗结果。最终用途细分主要集中在医院、诊断实验室和研究机构，透过治疗和诊断手段的进步推动市场需求。影响 CKD 市场的主要成长要素包括糖尿病和高血压盛行率的增加、诊断和治疗技术的进步以及政府的支持政策。潜在的机会在于个人化医疗和远端医疗服务的发展，以提供对患者的持续监测。公司应考虑投资人工智慧主导的诊断工具和穿戴式设备，以增强患者的依从性和监测，并有效解决未满足的临床需求。然而，市场成长面临治疗成本高、监管挑战以及患者对早期诊断和治疗依从性认识不足等限制。此外，人工智慧、机器学习和区块链等创新技术的整合有可能简化业务、提高患者诊断准确性并促进安全的患者资料管理。肾臟病学研究和针对 CKD 的先进生物製药的开发也可能推动业务成长。 CKD 市场是一个高度动态且以消费者为中心的市场，需要不断创新并适应监管和技术变化。透过跟上这些进步并专注于透过个人化医疗和数位健康解决方案改善患者的治疗结果，我们可以显着提高我们的市场占有率和盈利。考虑到这些因素，公司需要优先考虑策略联盟和研究伙伴关係，以有效利用新技术趋势。

主要市场统计
基准年[2023] 1284.5亿美元
预计年份 [2024] 1365.6亿美元
预测年份 [2030] 1996.4亿美元
复合年增长率（%） 6.50%

市场动态：揭示快速发展的慢性肾臟病市场的关键市场洞察

供需的动态交互作用正在改变慢性肾臟病市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 随着人口老化，慢性肾臟病的全球盛行率不断增加
    • 旨在改善医疗基础设施的政府和监管支援政策
    • 提高大众和医学界对肾臟疾病早期筛检和诊断的认识
  • 市场限制因素
    • 高成本，各地区产品标准化有差距
  • 市场机会
    • 治疗和诊断技术的进步以及产品创新
    • 远端医疗和远端监控技术的扩展
  • 市场挑战
    • 先进肾臟疾病治疗商业化的限制

波特五力：驾驭慢性肾臟病市场的策略工具

波特的五力框架是了解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解慢性肾臟病市场的外部影响

外部宏观环境因素在塑造慢性肾臟病市场的表现动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并帮助他们做出积极主动的决策。

市场占有率分析 了解慢性肾臟病市场的竞争格局

慢性肾臟病市场的详细市场占有率分析可以对供应商的绩效进行全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，使他们能够在日益激烈的竞争中占有一席之地。

FPNV慢性肾臟病市场定位矩阵供应商绩效评估

FPNV 定位矩阵是评估慢性肾臟病市场供应商的关键工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，并确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议描绘了慢性肾臟病市场的成功之路

慢性肾臟病市场的策略分析对于旨在加强其在全球市场的影响力的公司至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 随着人口老化，慢性肾臟病的全球盛行率增加
      • 旨在改善医疗基础设施的政府和监管支援政策
      • 提高大众和医学界对肾臟疾病早期筛检和诊断的认识
    • 抑制因素
      • 高成本，各地区产品标准化有差距
    • 机会
      • 治疗诊断技术及产品创新进展
      • 远端医疗和远端监控技术的扩展
    • 任务
      • 肾臟疾病进行性治疗方法的商业化有限
  • 市场区隔分析
    • 类型：对慢性肾臟病诊断解决方案以确定肾功能的需求不断增加
    • 最终使用者：医院和诊所提供广泛的服务，扩大慢性肾臟病治疗的范围。
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章慢性肾臟病市场：依类型

  • 诊断
    • 验血
    • 影像检查
    • 切片检查
    • 尿液检查
  • 治疗
    • 透析
    • 肾臟移植
    • 药物治疗
      • ACE抑制剂
      • 血管收缩素受体阻断剂
      • β受体阻断剂
      • 利尿剂
      • 促红血球生成素兴奋剂
      • Finerenone
      • Glucagon-Like Peptide-1受体促效剂
      • 胰岛素
      • Metformin
      • 钾粘合剂
      • 钠-葡萄糖共同输送体-2抑制剂
      • 他汀类药物

第七章慢性肾臟病市场（按适应症）

  • 慢性间质性肾炎
  • 糖尿病肾臟病
  • 肾丝球肾炎
  • 高血压肾臟病
  • 阻塞性肾臟病变
  • 多囊肾

第八章慢性肾臟病市场：依最终用户分类

  • 门诊手术中心
  • 诊断中心及实验室
  • 医院/诊所
  • 专门治疗中心

第九章美洲慢性肾臟病市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十章亚太地区慢性肾臟病市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十一章欧洲、中东和非洲慢性肾臟病市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十二章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • FDA核准Akebia Therapeutics 的 Vafseo 治疗 CKD 患者贫血
    • FDA核准慢性肾臟病治疗 Jardiance(R)，并指定非建议用途
    • Signify Health 为 Medicare Advantage 会员推出家庭肾臟健康评估
  • 战略分析和建议

公司名单

  • AbbVie Inc.
  • Allmed Medical Products Co., Ltd.
  • AngioDynamics, Inc.
  • Apotex Inc.
  • Asahi Kasei Corporation
  • AstraZeneca PLC
  • B. Braun SE
  • Baxter International, Inc.
  • Becton, Dickinson and Company
  • Centessa Pharmaceuticals Limited
  • DaVita Inc.
  • Dialife SA
  • Dr. Reddys Laboratories Ltd.
  • Evoqua Water Technologies LLC
  • Fresenius Medical Care AG
  • Galapagos NV
  • Hemoclean Co. Ltd.
  • JMS Co., Ltd.
  • Johnson & Johnson Services, Inc.
  • Medtronic PLC
  • Merck & Co., Inc.
  • Nikkiso Co., Ltd.
  • Nipro Corporation
  • Novartis AG
  • NxStage Medical Inc.
  • Otsuka Pharmaceutical Co., Ltd.
  • Reata Pharmaceuticals Inc.
  • Rockwell Medical Inc.
  • Sanofi SA
  • Teva Pharmaceutical Industries Ltd.
  • Toray Medical Co., Ltd.
  • Trivitron Healthcare
  • XORTX Therapeutics Inc.
Product Code: MRR-99555D550528

The Chronic Kidney Disease Market was valued at USD 128.45 billion in 2023, expected to reach USD 136.56 billion in 2024, and is projected to grow at a CAGR of 6.50%, to USD 199.64 billion by 2030.

Chronic Kidney Disease (CKD) refers to a long-term condition characterized by gradual loss of kidney function, affecting millions globally due to factors such as diabetes and hypertension. The market scope includes pharmaceuticals, diagnostics, dialyzers, and renal transplantation, marking a critical necessity in the healthcare sector. CKD management involves early diagnosis, monitoring, treatment adherence, and consulting specialized clinics, addressing both healthcare providers' needs and enhancing patient outcomes. The end-use segmentation primarily focuses on hospitals, diagnostic laboratories, and research institutes, driving market demand through advancements in therapeutic and diagnostic measures. Key growth factors influencing the CKD market include increasing prevalence of diabetes and hypertension, technological advancements in diagnostic and treatment procedures, and supportive governmental policies. Potential opportunities lie in developing personalized medicine and telehealth services to provide continuous patient monitoring. Companies should consider investments in AI-driven diagnostic tools and wearable devices to enhance patient adherence and monitoring, addressing unmet clinical needs effectively. However, market growth faces limitations such as high treatment costs, regulatory challenges, and inadequate awareness among patients about early diagnosis and treatment adherence. Furthermore, the integration of innovative technologies like AI, machine learning, and blockchain could streamline operations, improve patient diagnosis accuracy, and facilitate secure patient data management. Research into nephrology and development of advanced biopharmaceuticals tailored for CKD can also propel business growth. The CKD market is highly dynamic and consumer-centric, demanding constant innovation and adaptation to regulatory and technological changes. Keeping pace with these advancements and focusing on improving patient outcomes through personalized care and digital health solutions can significantly enhance market presence and profitability. In light of these factors, companies should prioritize strategic collaborations and research partnerships to harness emerging technological trends effectively.

KEY MARKET STATISTICS
Base Year [2023] USD 128.45 billion
Estimated Year [2024] USD 136.56 billion
Forecast Year [2030] USD 199.64 billion
CAGR (%) 6.50%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Chronic Kidney Disease Market

The Chronic Kidney Disease Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Increasing global prevalence of chronic kidney disease with the aging population
    • Supportive government and regulatory policies aimed at improving healthcare infrastructure
    • Growing public and medical community awareness regarding early screening and diagnosis of kidney ailments
  • Market Restraints
    • High cost and gap in product standardization across regions
  • Market Opportunities
    • Advancements in treatment and diagnostic technologies and product innovation
    • Expansion of telemedicine and remote monitoring technologies
  • Market Challenges
    • Limited commercialization of advanced kidney disease treatments

Porter's Five Forces: A Strategic Tool for Navigating the Chronic Kidney Disease Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Chronic Kidney Disease Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Chronic Kidney Disease Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Chronic Kidney Disease Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Chronic Kidney Disease Market

A detailed market share analysis in the Chronic Kidney Disease Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Chronic Kidney Disease Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Chronic Kidney Disease Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Chronic Kidney Disease Market

A strategic analysis of the Chronic Kidney Disease Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Chronic Kidney Disease Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Allmed Medical Products Co., Ltd., AngioDynamics, Inc., Apotex Inc., Asahi Kasei Corporation, AstraZeneca PLC, B. Braun SE, Baxter International, Inc., Becton, Dickinson and Company, Centessa Pharmaceuticals Limited, DaVita Inc., Dialife SA, Dr. Reddys Laboratories Ltd., Evoqua Water Technologies LLC, Fresenius Medical Care AG, Galapagos NV, Hemoclean Co. Ltd., JMS Co., Ltd., Johnson & Johnson Services, Inc., Medtronic PLC, Merck & Co., Inc., Nikkiso Co., Ltd., Nipro Corporation, Novartis AG, NxStage Medical Inc., Otsuka Pharmaceutical Co., Ltd., Reata Pharmaceuticals Inc., Rockwell Medical Inc., Sanofi S.A., Teva Pharmaceutical Industries Ltd., Toray Medical Co., Ltd., Trivitron Healthcare, and XORTX Therapeutics Inc..

Market Segmentation & Coverage

This research report categorizes the Chronic Kidney Disease Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Type, market is studied across Diagnosis and Treatment. The Diagnosis is further studied across Blood Tests, Imaging Tests, Kidney Biopsy, and Urine Tests. The Treatment is further studied across Dialysis, Kidney Transplant, and Medication. The Medication is further studied across ACE Inhibitors, Angiotensin Receptor Blockers, Beta Blockers, Diuretics, Erythropoietin Stimulants, Finerenone, Glucagon-like Peptide-1 Receptor Agonists, Insulin, Metformin, Potassium Binders, Sodium-glucose Cotransporter-2 Inhibitors, and Statins.
  • Based on Indication, market is studied across Chronic Interstitial Nephritis, Diabetic Nephropathy, Glomerulonephritis, Hypertensive Nephropathy, Obstructive Nephropathy, and Polycystic Kidney Disease.
  • Based on End-User, market is studied across Ambulatory Surgery Centers, Diagnostic Centers & Laboratories, Hospitals & Clinics, and Speciality Treatment Centers.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Increasing global prevalence of chronic kidney disease with the aging population
      • 5.1.1.2. Supportive government and regulatory policies aimed at improving healthcare infrastructure
      • 5.1.1.3. Growing public and medical community awareness regarding early screening and diagnosis of kidney ailments
    • 5.1.2. Restraints
      • 5.1.2.1. High cost and gap in product standardization across regions
    • 5.1.3. Opportunities
      • 5.1.3.1. Advancements in treatment and diagnostic technologies and product innovation
      • 5.1.3.2. Expansion of telemedicine and remote monitoring technologies
    • 5.1.4. Challenges
      • 5.1.4.1. Limited commercialization of advanced kidney disease treatments
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Type: Growing need for chronic kidney disease diagnosis solutions to determine the function of the kidneys
    • 5.2.2. End-User: Growing accessibility of chronic kidney disease treatments through hospitals & clinics as they offer a broad range of services
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Chronic Kidney Disease Market, by Type

  • 6.1. Introduction
  • 6.2. Diagnosis
    • 6.2.1. Blood Tests
    • 6.2.2. Imaging Tests
    • 6.2.3. Kidney Biopsy
    • 6.2.4. Urine Tests
  • 6.3. Treatment
    • 6.3.1. Dialysis
    • 6.3.2. Kidney Transplant
    • 6.3.3. Medication
      • 6.3.3.1. ACE Inhibitors
      • 6.3.3.2. Angiotensin Receptor Blockers
      • 6.3.3.3. Beta Blockers
      • 6.3.3.4. Diuretics
      • 6.3.3.5. Erythropoietin Stimulants
      • 6.3.3.6. Finerenone
      • 6.3.3.7. Glucagon-like Peptide-1 Receptor Agonists
      • 6.3.3.8. Insulin
      • 6.3.3.9. Metformin
      • 6.3.3.10. Potassium Binders
      • 6.3.3.11. Sodium-glucose Cotransporter-2 Inhibitors
      • 6.3.3.12. Statins

7. Chronic Kidney Disease Market, by Indication

  • 7.1. Introduction
  • 7.2. Chronic Interstitial Nephritis
  • 7.3. Diabetic Nephropathy
  • 7.4. Glomerulonephritis
  • 7.5. Hypertensive Nephropathy
  • 7.6. Obstructive Nephropathy
  • 7.7. Polycystic Kidney Disease

8. Chronic Kidney Disease Market, by End-User

  • 8.1. Introduction
  • 8.2. Ambulatory Surgery Centers
  • 8.3. Diagnostic Centers & Laboratories
  • 8.4. Hospitals & Clinics
  • 8.5. Speciality Treatment Centers

9. Americas Chronic Kidney Disease Market

  • 9.1. Introduction
  • 9.2. Argentina
  • 9.3. Brazil
  • 9.4. Canada
  • 9.5. Mexico
  • 9.6. United States

10. Asia-Pacific Chronic Kidney Disease Market

  • 10.1. Introduction
  • 10.2. Australia
  • 10.3. China
  • 10.4. India
  • 10.5. Indonesia
  • 10.6. Japan
  • 10.7. Malaysia
  • 10.8. Philippines
  • 10.9. Singapore
  • 10.10. South Korea
  • 10.11. Taiwan
  • 10.12. Thailand
  • 10.13. Vietnam

11. Europe, Middle East & Africa Chronic Kidney Disease Market

  • 11.1. Introduction
  • 11.2. Denmark
  • 11.3. Egypt
  • 11.4. Finland
  • 11.5. France
  • 11.6. Germany
  • 11.7. Israel
  • 11.8. Italy
  • 11.9. Netherlands
  • 11.10. Nigeria
  • 11.11. Norway
  • 11.12. Poland
  • 11.13. Qatar
  • 11.14. Russia
  • 11.15. Saudi Arabia
  • 11.16. South Africa
  • 11.17. Spain
  • 11.18. Sweden
  • 11.19. Switzerland
  • 11.20. Turkey
  • 11.21. United Arab Emirates
  • 11.22. United Kingdom

12. Competitive Landscape

  • 12.1. Market Share Analysis, 2023
  • 12.2. FPNV Positioning Matrix, 2023
  • 12.3. Competitive Scenario Analysis
    • 12.3.1. FDA Approves Akebia Therapeutics' Vafseo for Treatment of Anemia in CKD Patients
    • 12.3.2. FDA Approves Jardiance(R) for Chronic Kidney Disease, Specifies Non-Recommended Uses
    • 12.3.3. Signify Health Launches In-Home Kidney Health Evaluations for Medicare Advantage Members
  • 12.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AbbVie Inc.
  • 2. Allmed Medical Products Co., Ltd.
  • 3. AngioDynamics, Inc.
  • 4. Apotex Inc.
  • 5. Asahi Kasei Corporation
  • 6. AstraZeneca PLC
  • 7. B. Braun SE
  • 8. Baxter International, Inc.
  • 9. Becton, Dickinson and Company
  • 10. Centessa Pharmaceuticals Limited
  • 11. DaVita Inc.
  • 12. Dialife SA
  • 13. Dr. Reddys Laboratories Ltd.
  • 14. Evoqua Water Technologies LLC
  • 15. Fresenius Medical Care AG
  • 16. Galapagos NV
  • 17. Hemoclean Co. Ltd.
  • 18. JMS Co., Ltd.
  • 19. Johnson & Johnson Services, Inc.
  • 20. Medtronic PLC
  • 21. Merck & Co., Inc.
  • 22. Nikkiso Co., Ltd.
  • 23. Nipro Corporation
  • 24. Novartis AG
  • 25. NxStage Medical Inc.
  • 26. Otsuka Pharmaceutical Co., Ltd.
  • 27. Reata Pharmaceuticals Inc.
  • 28. Rockwell Medical Inc.
  • 29. Sanofi S.A.
  • 30. Teva Pharmaceutical Industries Ltd.
  • 31. Toray Medical Co., Ltd.
  • 32. Trivitron Healthcare
  • 33. XORTX Therapeutics Inc.

LIST OF FIGURES

  • FIGURE 1. CHRONIC KIDNEY DISEASE MARKET RESEARCH PROCESS
  • FIGURE 2. CHRONIC KIDNEY DISEASE MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. AMERICAS CHRONIC KIDNEY DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 13. AMERICAS CHRONIC KIDNEY DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. UNITED STATES CHRONIC KIDNEY DISEASE MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 15. UNITED STATES CHRONIC KIDNEY DISEASE MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. ASIA-PACIFIC CHRONIC KIDNEY DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 17. ASIA-PACIFIC CHRONIC KIDNEY DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. EUROPE, MIDDLE EAST & AFRICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. EUROPE, MIDDLE EAST & AFRICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. CHRONIC KIDNEY DISEASE MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 21. CHRONIC KIDNEY DISEASE MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CHRONIC KIDNEY DISEASE MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CHRONIC KIDNEY DISEASE MARKET DYNAMICS
  • TABLE 7. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY BLOOD TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY IMAGING TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY KIDNEY BIOPSY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY URINE TESTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIALYSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY KIDNEY TRANSPLANT, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY ACE INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY ANGIOTENSIN RECEPTOR BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY BETA BLOCKERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIURETICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY ERYTHROPOIETIN STIMULANTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY FINERENONE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY INSULIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY METFORMIN, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY POTASSIUM BINDERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY SODIUM-GLUCOSE COTRANSPORTER-2 INHIBITORS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY STATINS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY CHRONIC INTERSTITIAL NEPHRITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIABETIC NEPHROPATHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 35. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY GLOMERULONEPHRITIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 36. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY HYPERTENSIVE NEPHROPATHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 37. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY OBSTRUCTIVE NEPHROPATHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 38. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY POLYCYSTIC KIDNEY DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 39. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 40. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY AMBULATORY SURGERY CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 41. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSTIC CENTERS & LABORATORIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 42. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY HOSPITALS & CLINICS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 43. GLOBAL CHRONIC KIDNEY DISEASE MARKET SIZE, BY SPECIALITY TREATMENT CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 44. AMERICAS CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. AMERICAS CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 46. AMERICAS CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 47. AMERICAS CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 48. AMERICAS CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 49. AMERICAS CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 50. AMERICAS CHRONIC KIDNEY DISEASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 51. ARGENTINA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 52. ARGENTINA CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 53. ARGENTINA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 54. ARGENTINA CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 55. ARGENTINA CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 56. ARGENTINA CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 57. BRAZIL CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. BRAZIL CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 59. BRAZIL CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 60. BRAZIL CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 61. BRAZIL CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 62. BRAZIL CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 63. CANADA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. CANADA CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 65. CANADA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 66. CANADA CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 67. CANADA CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 68. CANADA CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. MEXICO CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. MEXICO CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 71. MEXICO CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 72. MEXICO CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 73. MEXICO CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 74. MEXICO CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 75. UNITED STATES CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. UNITED STATES CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 77. UNITED STATES CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 78. UNITED STATES CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 79. UNITED STATES CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 80. UNITED STATES CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. UNITED STATES CHRONIC KIDNEY DISEASE MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 82. ASIA-PACIFIC CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 83. ASIA-PACIFIC CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 84. ASIA-PACIFIC CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 85. ASIA-PACIFIC CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 86. ASIA-PACIFIC CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 87. ASIA-PACIFIC CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 88. ASIA-PACIFIC CHRONIC KIDNEY DISEASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 89. AUSTRALIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. AUSTRALIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 91. AUSTRALIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 92. AUSTRALIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 93. AUSTRALIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 94. AUSTRALIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 95. CHINA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. CHINA CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 97. CHINA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 98. CHINA CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 99. CHINA CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 100. CHINA CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 101. INDIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 102. INDIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 103. INDIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 104. INDIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 105. INDIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 106. INDIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 107. INDONESIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 108. INDONESIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 109. INDONESIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 110. INDONESIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 111. INDONESIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 112. INDONESIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 113. JAPAN CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 114. JAPAN CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 115. JAPAN CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 116. JAPAN CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 117. JAPAN CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 118. JAPAN CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 119. MALAYSIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 120. MALAYSIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 121. MALAYSIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 122. MALAYSIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 123. MALAYSIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 124. MALAYSIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 125. PHILIPPINES CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 126. PHILIPPINES CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 127. PHILIPPINES CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 128. PHILIPPINES CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 129. PHILIPPINES CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 130. PHILIPPINES CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 131. SINGAPORE CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 132. SINGAPORE CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 133. SINGAPORE CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 134. SINGAPORE CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 135. SINGAPORE CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 136. SINGAPORE CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 137. SOUTH KOREA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 138. SOUTH KOREA CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 139. SOUTH KOREA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 140. SOUTH KOREA CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 141. SOUTH KOREA CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 142. SOUTH KOREA CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 143. TAIWAN CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 144. TAIWAN CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 145. TAIWAN CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 146. TAIWAN CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 147. TAIWAN CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 148. TAIWAN CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 149. THAILAND CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 150. THAILAND CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 151. THAILAND CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 152. THAILAND CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 153. THAILAND CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 154. THAILAND CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 155. VIETNAM CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 156. VIETNAM CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 157. VIETNAM CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 158. VIETNAM CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 159. VIETNAM CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 160. VIETNAM CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 161. EUROPE, MIDDLE EAST & AFRICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 162. EUROPE, MIDDLE EAST & AFRICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 163. EUROPE, MIDDLE EAST & AFRICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 164. EUROPE, MIDDLE EAST & AFRICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 165. EUROPE, MIDDLE EAST & AFRICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 166. EUROPE, MIDDLE EAST & AFRICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 167. EUROPE, MIDDLE EAST & AFRICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 168. DENMARK CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 169. DENMARK CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 170. DENMARK CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 171. DENMARK CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 172. DENMARK CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 173. DENMARK CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 174. EGYPT CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 175. EGYPT CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 176. EGYPT CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 177. EGYPT CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 178. EGYPT CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 179. EGYPT CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 180. FINLAND CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 181. FINLAND CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 182. FINLAND CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 183. FINLAND CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 184. FINLAND CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 185. FINLAND CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 186. FRANCE CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 187. FRANCE CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 188. FRANCE CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 189. FRANCE CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 190. FRANCE CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 191. FRANCE CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 192. GERMANY CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 193. GERMANY CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 194. GERMANY CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 195. GERMANY CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 196. GERMANY CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 197. GERMANY CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 198. ISRAEL CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 199. ISRAEL CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 200. ISRAEL CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 201. ISRAEL CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 202. ISRAEL CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 203. ISRAEL CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 204. ITALY CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 205. ITALY CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 206. ITALY CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 207. ITALY CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 208. ITALY CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 209. ITALY CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 210. NETHERLANDS CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 211. NETHERLANDS CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 212. NETHERLANDS CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 213. NETHERLANDS CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 214. NETHERLANDS CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 215. NETHERLANDS CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 216. NIGERIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 217. NIGERIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 218. NIGERIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 219. NIGERIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 220. NIGERIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 221. NIGERIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 222. NORWAY CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 223. NORWAY CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 224. NORWAY CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 225. NORWAY CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 226. NORWAY CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 227. NORWAY CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 228. POLAND CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 229. POLAND CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 230. POLAND CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 231. POLAND CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 232. POLAND CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 233. POLAND CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 234. QATAR CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 235. QATAR CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 236. QATAR CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 237. QATAR CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 238. QATAR CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 239. QATAR CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 240. RUSSIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 241. RUSSIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 242. RUSSIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 243. RUSSIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 244. RUSSIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 245. RUSSIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 246. SAUDI ARABIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 247. SAUDI ARABIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 248. SAUDI ARABIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 249. SAUDI ARABIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 250. SAUDI ARABIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 251. SAUDI ARABIA CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 252. SOUTH AFRICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 253. SOUTH AFRICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 254. SOUTH AFRICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 255. SOUTH AFRICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 256. SOUTH AFRICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 257. SOUTH AFRICA CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 258. SPAIN CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 259. SPAIN CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 260. SPAIN CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 261. SPAIN CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 262. SPAIN CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 263. SPAIN CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 264. SWEDEN CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 265. SWEDEN CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 266. SWEDEN CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 267. SWEDEN CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 268. SWEDEN CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 269. SWEDEN CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 270. SWITZERLAND CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 271. SWITZERLAND CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 272. SWITZERLAND CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 273. SWITZERLAND CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 274. SWITZERLAND CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 275. SWITZERLAND CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 276. TURKEY CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 277. TURKEY CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 278. TURKEY CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 279. TURKEY CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 280. TURKEY CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 281. TURKEY CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 282. UNITED ARAB EMIRATES CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 283. UNITED ARAB EMIRATES CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 284. UNITED ARAB EMIRATES CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 285. UNITED ARAB EMIRATES CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 286. UNITED ARAB EMIRATES CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 287. UNITED ARAB EMIRATES CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 288. UNITED KINGDOM CHRONIC KIDNEY DISEASE MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
  • TABLE 289. UNITED KINGDOM CHRONIC KIDNEY DISEASE MARKET SIZE, BY DIAGNOSIS, 2018-2030 (USD MILLION)
  • TABLE 290. UNITED KINGDOM CHRONIC KIDNEY DISEASE MARKET SIZE, BY TREATMENT, 2018-2030 (USD MILLION)
  • TABLE 291. UNITED KINGDOM CHRONIC KIDNEY DISEASE MARKET SIZE, BY MEDICATION, 2018-2030 (USD MILLION)
  • TABLE 292. UNITED KINGDOM CHRONIC KIDNEY DISEASE MARKET SIZE, BY INDICATION, 2018-2030 (USD MILLION)
  • TABLE 293. UNITED KINGDOM CHRONIC KIDNEY DISEASE MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 294. CHRONIC KIDNEY DISEASE MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 295. CHRONIC KIDNEY DISEASE MARKET, FPNV POSITIONING MATRIX, 2023